Broken String Biosciences is building a technology platform that accelerates the characterisation of novel genome editing technologies. This will unlock the next wave of cell & gene therapies. Our vision is a future where cell & gene therapies are safer, more efficient, and affordable for patients. Starting with our DNA break mapping technology INDUCE-seq™, our data-driven platform reveals precisely how genome editors interact with and alter our genomes. This information is essential for the efficient development of novel genome editing systems and will unlock many new targets within the genome for therapeutic development. Broken String Biosciences is backed by Illumina and Tencent and is based at the Wellcome Genome Campus, Cambridge, UK.